ROCHE: "Intereses creados" (sin declaración de conflictos...)

THREE Melbourne oncologists say cancer treatment research published in one of the world's most prestigious medical journals may have been compromised by a drug company that funded the study.

Publication of the research in The Lancet may have boosted the drug's perceived value to doctors and patients around the world, helping its manufacturer, Roche, make billions of dollars from the product, they said.

In a letter sent to The Lancet last year, Associate Professor Ian Haines from Cabrini Hospital and two colleagues said they were concerned that 27 out of 32 authors of the research published last October had potential conflicts of interest, given they had declared various financial links to drug companies, including Roche.

Advertisement: Story continues below

One of these 27 authors was a paid employee of the company.

Más